Pub Date : 2022-03-01DOI: 10.1183/20734735.0218-2021
C. Ardura-Garcia, D. Kohlbrenner, Joana Cruz
In this article, we present the @EuroRespSoc opportunities for ECMs (@EarlyCareerERS) in the upcoming year and describe the experience of applying for an ERS Fellowship, with the key steps and challenges identified https://bit.ly/3nz5KlO
{"title":"Shape your career: opportunities for Early Career Members in 2022 and the experience of applying for an ERS fellowship","authors":"C. Ardura-Garcia, D. Kohlbrenner, Joana Cruz","doi":"10.1183/20734735.0218-2021","DOIUrl":"https://doi.org/10.1183/20734735.0218-2021","url":null,"abstract":"In this article, we present the @EuroRespSoc opportunities for ECMs (@EarlyCareerERS) in the upcoming year and describe the experience of applying for an ERS Fellowship, with the key steps and challenges identified https://bit.ly/3nz5KlO","PeriodicalId":9292,"journal":{"name":"Breathe","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48226209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-01DOI: 10.1183/20734735.0148-2021
M. Everard
I read with interest the review by Bush and Pavord [1] regarding the suggestion that we should abandon “umbrella” diagnoses and rather we should address “treatable traits” when looking after patients with airways disease. Unfortunately, aspects of their proposal are only likely to add to, rather than reduce, the current confusion regarding management of these conditions. More importantly, it seems to include some potentially very dangerous recommendations. While advocating for addressing “treatable traits” is admirable in that it reminds clinicians to consider the patient and not the disease, the use of this idea to promote dangerous changes in practice should be challenged. https://bit.ly/30VkP8Q
{"title":"Challenging the paradigm","authors":"M. Everard","doi":"10.1183/20734735.0148-2021","DOIUrl":"https://doi.org/10.1183/20734735.0148-2021","url":null,"abstract":"I read with interest the review by Bush and Pavord [1] regarding the suggestion that we should abandon “umbrella” diagnoses and rather we should address “treatable traits” when looking after patients with airways disease. Unfortunately, aspects of their proposal are only likely to add to, rather than reduce, the current confusion regarding management of these conditions. More importantly, it seems to include some potentially very dangerous recommendations. While advocating for addressing “treatable traits” is admirable in that it reminds clinicians to consider the patient and not the disease, the use of this idea to promote dangerous changes in practice should be challenged. https://bit.ly/30VkP8Q","PeriodicalId":9292,"journal":{"name":"Breathe","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47925008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-01DOI: 10.1183/20734735.0217-2021
A. Mathioudakis, C. Osadnik, A. Boots, M. Bradicich, Sabine Bartel, R. Gloeckl, Joana Cruz
In this article, we provide an overview of the impact that being part of the @EuroRespSoc activities can have on a professional career, through the voices of Early Career Members (@EarlyCareerERS) https://bit.ly/32sHNW2
{"title":"Inspiring stories: the impact that being part of ERS activities can have on a professional career","authors":"A. Mathioudakis, C. Osadnik, A. Boots, M. Bradicich, Sabine Bartel, R. Gloeckl, Joana Cruz","doi":"10.1183/20734735.0217-2021","DOIUrl":"https://doi.org/10.1183/20734735.0217-2021","url":null,"abstract":"In this article, we provide an overview of the impact that being part of the @EuroRespSoc activities can have on a professional career, through the voices of Early Career Members (@EarlyCareerERS) https://bit.ly/32sHNW2","PeriodicalId":9292,"journal":{"name":"Breathe","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44770433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-01DOI: 10.1183/20734735.0158-2021
K. Myall, J. Martinovic, A. West
The global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has had far-reaching impacts on patients with interstitial lung disease (ILD), from diagnosis to management. In addition, after infection, persistent parenchymal change is associated with ongoing symptoms and functional impairment even in patients without pre-existing lung disease. The challenge of investigating and treating these patients has often fallen to ILD physicians. This review therefore seeks to explore the relationship between COVID-19 and the interstitium, as well as the model of care for patients with pre-existing ILD and those patients with persistent disease following recovery from their initial infection. Educational aims To understand the impact of the COVID-19 pandemic on patients with existing interstitial lung disease. To explore the development of interstitial lung disease after COVID-19 infection. COVID-19 has had profound effects on patients with pre-existing interstitial lung disease, and there is growing interest in the effect on the lung parenchyma in patients recovering from acute infection. https://bit.ly/33M5s4x
{"title":"How COVID-19 interacts with interstitial lung disease","authors":"K. Myall, J. Martinovic, A. West","doi":"10.1183/20734735.0158-2021","DOIUrl":"https://doi.org/10.1183/20734735.0158-2021","url":null,"abstract":"The global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has had far-reaching impacts on patients with interstitial lung disease (ILD), from diagnosis to management. In addition, after infection, persistent parenchymal change is associated with ongoing symptoms and functional impairment even in patients without pre-existing lung disease. The challenge of investigating and treating these patients has often fallen to ILD physicians. This review therefore seeks to explore the relationship between COVID-19 and the interstitium, as well as the model of care for patients with pre-existing ILD and those patients with persistent disease following recovery from their initial infection. Educational aims To understand the impact of the COVID-19 pandemic on patients with existing interstitial lung disease. To explore the development of interstitial lung disease after COVID-19 infection. COVID-19 has had profound effects on patients with pre-existing interstitial lung disease, and there is growing interest in the effect on the lung parenchyma in patients recovering from acute infection. https://bit.ly/33M5s4x","PeriodicalId":9292,"journal":{"name":"Breathe","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47677977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-01DOI: 10.1183/20734735.0168-2021
S. Cullivan, B. McCullagh, S. Gaine
This case of progressive dyspnoea in a 43-year-old with idiopathic non-cirrhotic portal hypertension highlights important pulmonary vascular complications of chronic liver disease https://bit.ly/3rwEkhP
{"title":"Progressive dyspnoea in a patient with idiopathic non-cirrhotic portal hypertension","authors":"S. Cullivan, B. McCullagh, S. Gaine","doi":"10.1183/20734735.0168-2021","DOIUrl":"https://doi.org/10.1183/20734735.0168-2021","url":null,"abstract":"This case of progressive dyspnoea in a 43-year-old with idiopathic non-cirrhotic portal hypertension highlights important pulmonary vascular complications of chronic liver disease https://bit.ly/3rwEkhP","PeriodicalId":9292,"journal":{"name":"Breathe","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43417417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-01DOI: 10.1183/20734735.0149-2021
C. Gill, Lorraine Dolan, L. Piggott, A. McLaughlin
Tuberculosis (TB) is a major cause of morbidity and mortality worldwide. It is estimated that 25% of the world's population are infected with Mycobacterium tuberculosis, with a 5–10% lifetime risk of progression into TB disease. Early recognition of TB disease and prompt detection of drug resistance are essential to halting its global burden. Culture, direct microscopy, biomolecular tests and whole genome sequencing are approved methods of diagnosis; however, their widespread use is often curtailed owing to costs, local resources, time constraints and operator efficiency. Methods of optimising these diagnostics, in addition to developing novel techniques, are under review. The selection of an appropriate drug regimen is dependent on the susceptibility pattern of the isolate detected. At present, there are 16 new drugs under evaluation for TB treatment in phase I or II clinical trials, with an additional 22 drugs in preclinical stages. Alongside the development of these new drugs, most of which are oral medications, new shorter regimes are under evaluation. The aim of these shorter regimens is to encourage patient adherence, and prevent relapse or the evolution of further drug resistance. Screening for TB infection, especially in vulnerable populations, provides an opportunity for intervention prior to progression towards infectious TB disease. New regimens are currently under evaluation to assess the efficacy of shorter durations of treatment in this population. In addition, there is extensive research into the use of post-exposure vaccinations in this cohort. Worldwide collaboration and sharing of expertise are essential to our ultimate aim of global eradication of TB disease. Educational aims Differentiate between TB infection and TB disease. Understand the different methods of diagnosing TB disease and resistance. Recognise the different drugs and regimens currently in use for TB disease. Be able to discuss risk of TB disease in TB infection, and assist patients in making an informed decision on treatment for TB infection. Early detection of drug resistance is essential to our goal of global eradication of TB. Tolerable drugs and shorter regimens promote patient adherence. Treating TB infection in vulnerable groups will prevent further global spread of TB disease. https://bit.ly/3oUW0SN
{"title":"New developments in tuberculosis diagnosis and treatment","authors":"C. Gill, Lorraine Dolan, L. Piggott, A. McLaughlin","doi":"10.1183/20734735.0149-2021","DOIUrl":"https://doi.org/10.1183/20734735.0149-2021","url":null,"abstract":"Tuberculosis (TB) is a major cause of morbidity and mortality worldwide. It is estimated that 25% of the world's population are infected with Mycobacterium tuberculosis, with a 5–10% lifetime risk of progression into TB disease. Early recognition of TB disease and prompt detection of drug resistance are essential to halting its global burden. Culture, direct microscopy, biomolecular tests and whole genome sequencing are approved methods of diagnosis; however, their widespread use is often curtailed owing to costs, local resources, time constraints and operator efficiency. Methods of optimising these diagnostics, in addition to developing novel techniques, are under review. The selection of an appropriate drug regimen is dependent on the susceptibility pattern of the isolate detected. At present, there are 16 new drugs under evaluation for TB treatment in phase I or II clinical trials, with an additional 22 drugs in preclinical stages. Alongside the development of these new drugs, most of which are oral medications, new shorter regimes are under evaluation. The aim of these shorter regimens is to encourage patient adherence, and prevent relapse or the evolution of further drug resistance. Screening for TB infection, especially in vulnerable populations, provides an opportunity for intervention prior to progression towards infectious TB disease. New regimens are currently under evaluation to assess the efficacy of shorter durations of treatment in this population. In addition, there is extensive research into the use of post-exposure vaccinations in this cohort. Worldwide collaboration and sharing of expertise are essential to our ultimate aim of global eradication of TB disease. Educational aims Differentiate between TB infection and TB disease. Understand the different methods of diagnosing TB disease and resistance. Recognise the different drugs and regimens currently in use for TB disease. Be able to discuss risk of TB disease in TB infection, and assist patients in making an informed decision on treatment for TB infection. Early detection of drug resistance is essential to our goal of global eradication of TB. Tolerable drugs and shorter regimens promote patient adherence. Treating TB infection in vulnerable groups will prevent further global spread of TB disease. https://bit.ly/3oUW0SN","PeriodicalId":9292,"journal":{"name":"Breathe","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47607953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-01DOI: 10.1183/20734735.0174-2021
Andrew Bush, I. Pavord
We thank M.L. Everard for his interest in our article [1] and thank the Editors for giving us the opportunity to respond. Space constraints precluded us describing the detailed management of extrapulmonary treatable traits, hence the educational aim was to begin to appreciate, but we are happy to refer interested readers to other review articles on the subject [2–4]. Inhaled corticosteroids should be targeted to those with documented airway eosinophilia, not prescribed indiscriminately to all who wheeze. Blind steroid treatment without regard to underlying pathophysiology is not 21st century standard of care. https://bit.ly/34lyaJG
{"title":"Reply to: Challenging the paradigm","authors":"Andrew Bush, I. Pavord","doi":"10.1183/20734735.0174-2021","DOIUrl":"https://doi.org/10.1183/20734735.0174-2021","url":null,"abstract":"We thank M.L. Everard for his interest in our article [1] and thank the Editors for giving us the opportunity to respond. Space constraints precluded us describing the detailed management of extrapulmonary treatable traits, hence the educational aim was to begin to appreciate, but we are happy to refer interested readers to other review articles on the subject [2–4]. Inhaled corticosteroids should be targeted to those with documented airway eosinophilia, not prescribed indiscriminately to all who wheeze. Blind steroid treatment without regard to underlying pathophysiology is not 21st century standard of care. https://bit.ly/34lyaJG","PeriodicalId":9292,"journal":{"name":"Breathe","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46946548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-12-01DOI: 10.1183/20734735.0144-2021
J. Kavanagh, A. Hearn, D. Jackson
There are now several monoclonal antibody (mAb) therapies (“biologics”) available to treat severe asthma. Omalizumab is an anti-IgE mAb and is licensed in severe allergic asthma. Current evidence suggests it may decrease exacerbations by augmenting deficient antiviral immune responses in asthma. Like all other biologics, clinical efficacy is greatest in those with elevated T2 biomarkers. Three biologics target the interleukin (IL)-5–eosinophil pathway, including mepolizumab and reslizumab that target IL-5 itself, and benralizumab that targets the IL-5 receptor (IL-5R-α). These drugs all reduce the exacerbation rate in those with raised blood eosinophil counts. Mepolizumab and benralizumab have also demonstrated steroid-sparing efficacy. Reslizumab is the only biologic that is given intravenously rather than by the subcutaneous route. Dupilumab targets the IL-4 receptor and like mepolizumab and benralizumab is effective at reducing exacerbation rate as well as oral corticosteroid requirements. It is also effective for the treatment of nasal polyposis and atopic dermatitis. Tezepelumab is an anti-TSLP (thymic stromal lymphopoietin) mAb that has recently completed phase 3 trials demonstrating significant reductions in exacerbation rate even at lower T2 biomarker thresholds. Many patients with severe asthma qualify for more than one biologic. To date, there are no head-to-head trials to aid physicians in this choice. However, post-hoc analyses have identified certain clinical characteristics that are associated with superior responses to some therapies. The presence of allergic and/or eosinophilic comorbidities, such as atopic dermatitis, nasal polyposis or eosinophilic granulomatosis with polyangiitis, that may additionally benefit by the choice of biologic should also be taken into consideration, as should patient preferences which may include dosing frequency. To date, all biologics have been shown to have excellent safety profiles. Biologic therapies target T2 inflammatory pathways and elevated FENO and/or blood eosinophil counts are associated with greater clinical efficacy. Choice of drug will depend on individual patient characteristics and preferences. https://bit.ly/3lHOsSQ
{"title":"A pragmatic guide to choosing biologic therapies in severe asthma","authors":"J. Kavanagh, A. Hearn, D. Jackson","doi":"10.1183/20734735.0144-2021","DOIUrl":"https://doi.org/10.1183/20734735.0144-2021","url":null,"abstract":"There are now several monoclonal antibody (mAb) therapies (“biologics”) available to treat severe asthma. Omalizumab is an anti-IgE mAb and is licensed in severe allergic asthma. Current evidence suggests it may decrease exacerbations by augmenting deficient antiviral immune responses in asthma. Like all other biologics, clinical efficacy is greatest in those with elevated T2 biomarkers. Three biologics target the interleukin (IL)-5–eosinophil pathway, including mepolizumab and reslizumab that target IL-5 itself, and benralizumab that targets the IL-5 receptor (IL-5R-α). These drugs all reduce the exacerbation rate in those with raised blood eosinophil counts. Mepolizumab and benralizumab have also demonstrated steroid-sparing efficacy. Reslizumab is the only biologic that is given intravenously rather than by the subcutaneous route. Dupilumab targets the IL-4 receptor and like mepolizumab and benralizumab is effective at reducing exacerbation rate as well as oral corticosteroid requirements. It is also effective for the treatment of nasal polyposis and atopic dermatitis. Tezepelumab is an anti-TSLP (thymic stromal lymphopoietin) mAb that has recently completed phase 3 trials demonstrating significant reductions in exacerbation rate even at lower T2 biomarker thresholds. Many patients with severe asthma qualify for more than one biologic. To date, there are no head-to-head trials to aid physicians in this choice. However, post-hoc analyses have identified certain clinical characteristics that are associated with superior responses to some therapies. The presence of allergic and/or eosinophilic comorbidities, such as atopic dermatitis, nasal polyposis or eosinophilic granulomatosis with polyangiitis, that may additionally benefit by the choice of biologic should also be taken into consideration, as should patient preferences which may include dosing frequency. To date, all biologics have been shown to have excellent safety profiles. Biologic therapies target T2 inflammatory pathways and elevated FENO and/or blood eosinophil counts are associated with greater clinical efficacy. Choice of drug will depend on individual patient characteristics and preferences. https://bit.ly/3lHOsSQ","PeriodicalId":9292,"journal":{"name":"Breathe","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44615345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-12-01DOI: 10.1183/20734735.1741-2021
Breathe is voluntarily reviewed. We are most grateful to the hard work and dedication of those listed below, who reviewed articles for Breathe in 2021.
{"title":"Breathe, list of peer reviewers 2021","authors":"","doi":"10.1183/20734735.1741-2021","DOIUrl":"https://doi.org/10.1183/20734735.1741-2021","url":null,"abstract":"Breathe is voluntarily reviewed. We are most grateful to the hard work and dedication of those listed below, who reviewed articles for Breathe in 2021.","PeriodicalId":9292,"journal":{"name":"Breathe","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43367594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-12-01DOI: 10.1183/20734735.0146-2021
E. Tenda, M. Asaf, Ariel Pradipta, M. Kumaheri, A. P. Susanto
Through the implementation of a test and trace system, disciplined public health measures, the acceleration of vaccinations, and a genome surveillance programme, LMICs such as Indonesia can prevent future outbreaks and survive the COVID-19 pandemic. https://bit.ly/3JBBSie From June 2021 until August 2021, Indonesia experienced an unprecedented surge in the number of daily new confirmed coronavirus disease 2019 (COVID-19) cases. We, as authors who saw these events unfold first-hand, would like to describe the extent of Indonesia's COVID-19 case surge, its effect on the healthcare system, and the fallout, in this editorial. Moreover, we aim to identify the root of the problems that could have caused the recent surge, and subsequently propose possible solutions.
{"title":"The COVID-19 surge in Indonesia: what we learned and what to expect","authors":"E. Tenda, M. Asaf, Ariel Pradipta, M. Kumaheri, A. P. Susanto","doi":"10.1183/20734735.0146-2021","DOIUrl":"https://doi.org/10.1183/20734735.0146-2021","url":null,"abstract":"Through the implementation of a test and trace system, disciplined public health measures, the acceleration of vaccinations, and a genome surveillance programme, LMICs such as Indonesia can prevent future outbreaks and survive the COVID-19 pandemic. https://bit.ly/3JBBSie From June 2021 until August 2021, Indonesia experienced an unprecedented surge in the number of daily new confirmed coronavirus disease 2019 (COVID-19) cases. We, as authors who saw these events unfold first-hand, would like to describe the extent of Indonesia's COVID-19 case surge, its effect on the healthcare system, and the fallout, in this editorial. Moreover, we aim to identify the root of the problems that could have caused the recent surge, and subsequently propose possible solutions.","PeriodicalId":9292,"journal":{"name":"Breathe","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47279525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：